Product Description
Mechanisms of Action: HDAC Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Helsinn Healthcare
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Myeloid Leukemia
Phase 2: Myelofibrosis|Acute Myeloid Leukemia|Thrombocythemia, Essential|Myelodysplastic Syndrome|Polycythemia Vera|Myeloproliferative Disorders|Preleukemia|Prostate Cancer|Sarcoma
Phase 1: Oncology Solid Tumor Unspecified|Myelodysplastic Syndrome|Preleukemia|Healthy Volunteers|Acute Myeloid Leukemia|Tobacco Use Disorder|Leukemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2016-004724-34 |
2016-004724-34 | N/A |
Terminated |
Acute Myeloid Leukemia |
2020-07-02 |
2025-07-09 |
Treatments |
|
ACTRN12618001331224p |
2006-7041-83/hah | N/A |
Not yet recruiting |
Suicidality |
2019-01-31 |
|||
NCT03848754 |
PRO 33922 | P1 |
Completed |
Acute Myeloid Leukemia |
2021-05-05 |
2022-07-01 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT03495934 |
PRAN-17-17 | P1 |
Completed |
Healthy Volunteers |
2018-02-28 |
59% |
2019-08-10 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Trial Status |
NCT02118909 |
MEI-007 | P1 |
Completed |
Tobacco Use Disorder |
2014-06-01 |
2024-11-27 |
Primary Endpoints |
|
NCT02058784 |
HVFE | P1 |
Completed |
Tobacco Use Disorder |
2014-03-01 |
2019-03-20 |
Treatments |
|
NCT01184274 |
I203 | P1 |
Completed |
Leukemia |
2012-04-12 |
2023-08-05 |
Primary Endpoints|Start Date|Treatments |
|
NCT00741234 |
SB939-2006-001 | P1 |
Completed |
Preleukemia|Myelodysplastic Syndrome |
2012-03-01 |
2019-03-18 |
Treatments |
|
NCT00504296 |
I188 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2010-04-22 |
2023-08-05 |
Primary Endpoints|Start Date|Treatments |
|
NCT03151304 |
MEI-011 | P2 |
Terminated |
Preleukemia|Myelodysplastic Syndrome |
2020-12-01 |
38% |
2022-03-03 |
|
NCT02267278 |
NCI-2015-00002 | P2 |
Completed |
Myeloproliferative Disorders|Myelofibrosis |
2018-06-01 |
36% |
2019-03-20 |
Treatments |
NCT01912274 |
MEI-004 | P2 |
Completed |
Acute Myeloid Leukemia |
2016-11-08 |
2021-02-11 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
|
NCT01873703 |
MEI-003 | P2 |
Completed |
Myelodysplastic Syndrome|Preleukemia |
2015-11-01 |
2019-03-19 |
Treatments |
|
NCT01993641 |
MEI-005 | P2 |
Completed |
Preleukemia|Myelodysplastic Syndrome |
2015-05-01 |
2019-03-20 |
Treatments |
|
NCT01075308 |
I195 | P2 |
Completed |
Prostate Cancer |
2015-01-05 |
2023-08-05 |
Primary Endpoints|Start Date|Treatments |
|
NCT01112384 |
IND200 | P2 |
Completed |
Sarcoma |
2013-01-21 |
2023-08-05 |
Primary Endpoints|Start Date|Treatments |
|
NCT01200498 |
NCT01200498 | P2 |
Completed |
Thrombocythemia, Essential|Polycythemia Vera|Myelofibrosis|Myeloproliferative Disorders |
2012-11-01 |
2019-03-19 |
Treatments |
|
NCT03151408 |
PRAN-16-52 | P3 |
Terminated |
Acute Myeloid Leukemia |
2020-08-20 |
43% |
2024-06-26 |
Primary Endpoints|Treatments |
CTR20191971 |
CTR20191971 | P3 |
Terminated |
Acute Myeloid Leukemia |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |